BioSpace News Archive

Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, participated in groundbreaking research that demonstrates that the mortality rate among kidney failure patients can be significantly reduced through the utilization of high-dose hemodiafiltration technology.

Acurx Pharmaceuticals, Inc. announced today that David P. Luci, President & CEO, will present at the Emerging Growth Conference.

Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced it has received a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through its Therapeutic Pipeline Program.

Bionano Genomics, Inc. (BNGO), today announced the publication in Cancers of a peer-reviewed study from Augusta University on the utility of combining optical genome mapping (OGM) and a 523-gene next-generation sequencing (NGS) panel for the standard evaluation of myeloid cancers.

SEED Therapeutics, a BeyondSpring subsidiary and global research company focused on harnessing and engineering “molecular glues,” a targeted protein degradation platform to attack previously believed undruggable targets, announced that it has appointed Jackson Tai to its Board of Directors.

Regulus Therapeutics Inc today announced an update on its preclinical studies evaluating a library of oligonucleotides designed to inhibit miR-155 for the treatment of Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s disease).

PixCell Medical today announced that Guy Frak has been appointed chief commercial officer, effective immediately.

DiamiR Biosciences today announced that it will present two posters at the Alzheimer’s Association International Conference (AAIC), taking place July 16 – 20, 2023, in Amsterdam, Netherlands.

Avinger, Inc. today announced two podium presentations featuring the company’s Lumivascular technology at the Leipzig Interventional Course (LINC) 2023, which took place June 6 through June 9.

Simulations Plus, Inc. today announced the acquisition of Immunetrics, Inc. (“Immunetrics”), a modeling and simulation company focused on accelerating drug development in oncology, immunology, and autoimmune diseases.